Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Investment analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Thursday, August 6th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of ($3.33) per share for the year, down from their previous forecast of ($2.68). HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($1.42) EPS, Q2 2027 earnings at ($1.64) EPS, Q3 2027 earnings at ($1.65) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($4.14) EPS, FY2029 earnings at ($1.37) EPS and FY2030 earnings at $5.42 EPS.
Several other research analysts have also recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. JPMorgan Chase & Co. lifted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Chardan Capital boosted their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Weiss Ratings downgraded shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Finally, Sanford C. Bernstein raised their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.33.
Arrowhead Pharmaceuticals Stock Up 0.8%
ARWR stock opened at $88.33 on Monday. The stock has a market cap of $12.44 billion, a P/E ratio of -39.26 and a beta of 1.27. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a twelve month low of $15.81 and a twelve month high of $95.49. The company’s 50 day moving average is $80.23 and its two-hundred day moving average is $71.64.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period last year, the company earned ($1.26) earnings per share.
Hedge Funds Weigh In On Arrowhead Pharmaceuticals
Hedge funds have recently modified their holdings of the business. Tsfg LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. raised its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Versant Capital Management Inc boosted its stake in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
Featured Articles
- Five stocks we like better than Arrowhead Pharmaceuticals
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
